Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Payables (2017 - 2025)

Cue Biopharma's Payables history spans 9 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Payables fell 63.73% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, down 63.73%, while the annual FY2024 figure was $2.8 million, 19.37% down from the prior year.
  • Payables for Q3 2025 was $2.3 million at Cue Biopharma, down from $3.6 million in the prior quarter.
  • Across five years, Payables topped out at $6.5 million in Q3 2024 and bottomed at $1.6 million in Q2 2022.
  • The 5-year median for Payables is $2.6 million (2022), against an average of $3.0 million.
  • The largest annual shift saw Payables surged 161.05% in 2024 before it crashed 63.73% in 2025.
  • A 5-year view of Payables shows it stood at $2.6 million in 2021, then rose by 5.42% to $2.7 million in 2022, then grew by 28.19% to $3.5 million in 2023, then decreased by 19.37% to $2.8 million in 2024, then fell by 16.83% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Payables are $2.3 million (Q3 2025), $3.6 million (Q2 2025), and $3.8 million (Q1 2025).